Earlier this week, Halozyme Therapeutics’ subsidiary Halozyme Hypercon announced a global exclusive collaboration and license agreement granting Vertex Pharmaceuticals access to its Hypercon ...
Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $612 from $596 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma coverage for ...
As drugmakers strive to fine tune the delivery of their medications for better convenience and patient adherence, Halozyme is putting a recent acquisition in the space to work, thanks to a new tie- | ...
With a market cap of $112.9 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a biotechnology company focused on developing and commercializing innovative therapies, best known for its leading ...
Vertex Pharmaceuticals (NASDAQ: VRTX) experienced several setbacks last year, sometimes following quarterly updates that weren't as strong as the market expected, or during which it also reported ...
Zacks Investment Research on MSN
Vertex Pharmaceuticals Incorporated (VRTX) is a trending stock: Facts to know before betting on it
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
Vertex Pharmaceuticals (NASDAQ:VRTX) is set to give its latest quarterly earnings report on Thursday, 2026-02-12. Here's what investors need to know before the announcement. Analysts estimate that ...
Vertex Pharmaceuticals could have several important catalysts this year. The stock's long-term outlook seems highly attractive. Vertex Pharmaceuticals' strategy is to develop medicines in areas with ...
Investors with a lot of money to spend have taken a bearish stance on Vertex Pharmaceuticals (NASDAQ:VRTX). And retail traders should know. We noticed this today when the positions showed up on ...
Vertex Pharmaceuticals (NASDAQ: VRTX) has significantly underperformed broader equities over the past 12 months, with its shares down 10% since March of 2025, compared to a 15% gain for the S&P 500.
Vertex Pharmaceuticals received FDA approval for expanded use of its cystic fibrosis therapies, increasing the number of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results